Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.
Who is at the highest risk for developing type 2 diabetes in their youth? What are the consequences of being diagnosed so young, and what can clinicians do to help? Browse the hub to find out
Sanjay Kalra considers the course of action when blood glucose remains high in someone who cannot, or will not, modify a high-carbohydrate diet. Read more
Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.
People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.
Screening people with type 1 diabetes for albuminuria at intervals determined by their baseline albumin excretion rate and glycated hemoglobin level reduces the time spent with undetected kidney disease, show DCCT/EDIC data.
Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.
Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.
The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.
A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.
Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.